AlpC Polysaccharide Conjugate for Broad GBS Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Group B Streptococcus (GBS) infections have limitations in providing broad protective immunity, as they often focus on specific serotypes and may not effectively cover all clinically important strains, leading to incomplete protection against GBS infections, particularly type III strains which cause severe meningitis.
Innovation Solution
An immunogenic complex comprising an N-terminal region of a Group B Streptococcus surface protein and a capsular polysaccharide is developed, which acts as a carrier for the polysaccharide, enhancing immunogenicity and scope of protection by combining the strengths of earlier capsular polysaccharide and fusion protein techniques, thereby providing wide coverage against multiple GBS strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional capsular polysaccharide vaccines are used, then protection against specific serotypes is achieved, but broad protective immunity against multiple GBS strains is limited
Solution Approach 1:
The patent combines capsular polysaccharide (from type III GBS) with a carrier protein (AlpC N-terminal region) to create a conjugate vaccine. This composite structure leverages the immunogenicity of the polysaccharide while using the protein carrier to enhance T-cell dependent immunity, thereby achieving both specific protection against type III strains and broader cross-protection against other GBS strains through immune system activation
2Adaptability or versatility
If fusion protein techniques are used, then broader strain coverage is achieved, but immunogenicity may be insufficient compared to capsular polysaccharide approaches
Solution Approach 1:
The invention merges the advantages of capsular polysaccharide vaccines (high immunogenicity against specific serotypes) with fusion protein techniques (broad strain coverage). By conjugating the type III polysaccharide to the AlpC carrier protein that shows sequence homology across multiple GBS strains, the vaccine achieves both strong immune activation and broad protective immunity against diverse strains
3Reliability
If multiple vaccine components are used to cover all serotypes, then comprehensive protection is achieved, but vaccine complexity and cost increase
Solution Approach 1:
The AlpC carrier protein serves multiple functions: it acts as a conjugation carrier for the type III polysaccharide, provides T-cell epitopes for enhanced immunogenicity, and through its sequence homology across different GBS strains, provides broad cross-protection. This multi-functionality allows a single vaccine composition to target multiple strains without requiring separate components for each serotype
Data Source
AI summary
The present invention relates to an immunogenic complex comprising an amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a group B Streptococcus surface protein, and a capsular polysaccharide. The immunogenic complex is capable of eliciting protective immunity against group B Streptococcus. The invention further pertains to an immunogenic product comprising the immunogenic complex and an immunogenic fusion protein, the vaccine, the immunogenic complex, or the immunogenic product for use in a method of preventing or treating a group B Streptococcus infection, as well as a method of preventing or treating a group B Streptococcus infection.